Keyword Analysis & Research: ivacaftor
Keyword Research: People who searched ivacaftor also searched
Search Results related to ivacaftor on Search Engine
-
Ivacaftor - Wikipedia
https://en.wikipedia.org/wiki/Ivacaftor
WEBIvacaftor is a medication used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (primarily the G551D mutation), who account for 4–5% cases of cystic fibrosis.
DA: 66 PA: 79 MOZ Rank: 7
-
Ivacaftor: A Novel Gene-Based Therapeutic Approach for Cystic Fibrosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626070/
WEBIvacaftor is a new therapeutic agent that acts at the cystic fibrosis transmembrane conductance regulator (CFTR) channel to alter activity. It is approved for use in patients 6 years and older with cystic fibrosis who have at least 1 G551D mutation in the CFTR gene.
DA: 55 PA: 4 MOZ Rank: 69
-
Ivacaftor: MedlinePlus Drug Information
https://medlineplus.gov/druginfo/meds/a612012.html
WEBIvacaftor is used to treat certain types of cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction) in adults and children 1 month of age and older. Ivacaftor should be used only in people with a certain genetic make-up. Your doctor may order a blood test to help decide if this medication is right ...
DA: 3 PA: 24 MOZ Rank: 28
-
Ivacaftor (Oral Route) Description and Brand Names - Mayo Clinic
https://www.mayoclinic.org/drugs-supplements/ivacaftor-oral-route/description/drg-20075428
WEBIvacaftor is used to treat cystic fibrosis (CF). It is only used for patients who have the following mutations in their CF transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, R117H, S1251N, S1255P, S549N, or …
DA: 87 PA: 17 MOZ Rank: 28
-
Ivacaftor: Uses, Interactions, Mechanism of Action | DrugBank …
https://go.drugbank.com/drugs/DB08820
WEBIvacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator used alone or in combination products to treat cystic fibrosis in patients who have specific genetic mutations that are responsive to the medication.
DA: 25 PA: 15 MOZ Rank: 29
-
Ivacaftor: A Novel Mutation Modulating Drug - PMC - National …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290359/
WEBNov 20, 2014 · PMID: 25584290. Ivacaftor: A Novel Mutation Modulating Drug. Harit Kapoor, 1 Astha Koolwal, 2 and Ankur Singh 3. Author information Article notes Copyright and License information PMC Disclaimer. Go to: Abstract. Cystic fibrosis (CF) is multisystemic disorder presenting in newborn period to adulthood, predominantly …
DA: 77 PA: 79 MOZ Rank: 72
-
Ivacaftor Uses, Side Effects & Warnings - Drugs.com
https://www.drugs.com/mtm/ivacaftor.html
WEBAug 21, 2023 · What is ivacaftor? Ivacaftor is used to treat cystic fibrosis in adults and children who are at least 1 month old and weigh at least 6 pounds (3 kilograms). Ivacaftor tablet can be used in children aged 6 years and older. Ivacaftor granules can be used in children aged 1 month to under 6 years old.
DA: 21 PA: 50 MOZ Rank: 53
-
Ivacaftor Monograph for Professionals - Drugs.com
https://www.drugs.com/monograph/ivacaftor.html
WEBMar 10, 2024 · Introduction. A cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. Uses for Ivacaftor. Cystic Fibrosis. Treatment of cystic fibrosis in patients ≥1 month of age who have at least one mutation in the CFTR gene that is responsive to ivacaftor based on in vitro assay and/or clinical data.
DA: 62 PA: 55 MOZ Rank: 23
-
Lumacaftor and Ivacaftor: MedlinePlus Drug Information
https://medlineplus.gov/druginfo/meds/a615037.html
WEBWhy is this medication prescribed? Lumacaftor and ivacaftor is used to treat certain types of cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction) in adults and children 1 year of age and older.
DA: 100 PA: 24 MOZ Rank: 58
-
FDA expands approved use of Kalydeco to treat additional …
https://www.fda.gov/news-events/press-announcements/fda-expands-approved-use-kalydeco-treat-additional-mutations-cystic-fibrosis
WEBThe U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug...
DA: 26 PA: 25 MOZ Rank: 59
